Chest
Original ResearchSarcoidosisThe Treatment of Lupus Pernio: Results of 116 Treatment Courses in 54 Patients
Section snippets
Materials and Methods
This study was approved by the Medical University of South Carolina (MUSC) Institutional Review Board.
Results
Ninety-two patients with lupus pernio were identified from the sarcoidosis database. Nine patients had concomitant severe extracutaneous sarcoidosis (cardiac sarcoidosis, neurosarcoidosis, and severe pulmonary sarcoidosis) that was the primary reason for therapy and so were excluded from this analysis. Eleven patients had only a single visit and, therefore, the effect of therapy could not be assessed. Two patients had a history of lupus pernio but no active lesions and were not treated. No data
Discussion
Our study is clearly the largest to examine the treatment of lupus pernio with 116 separate treatment courses analyzed in 54 individual patients. The largest previous series13 of treatment of lupus pernio that we identified reported 30 patients. However, those authors13 mentioned that only 1 of their 30 patients had lupus pernio, although we believe that most of them had lupus pernio by virtue of their description of the skin lesions. In addition, the authors13 did not provide their methodology
Acknowledgment
The authors thank Dr. Sooyeon Kwon for assistance with data analysis.
References (33)
- et al.
Chronic cutaneous lesions of sarcoidosis
Clin Dermatol
(2007) - et al.
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
J Am Acad Dermatol
(1995) - et al.
Treatment of cutaneous sarcoidosis with thalidomide
J Am Acad Dermatol
(2004) - et al.
Treatment of sarcoidosis with infliximab
Chest
(2005) - et al.
Thalidomide for chronic sarcoidosis
Chest
(2002) - et al.
Weekly low-dose methotrexate therapy for cutaneous sarcoidosis
J Am Acad Dermatol
(1991) - et al.
Treatment of sarcoidosis with infliximab
Chest
(2005) - et al.
Lupus pernio: a clinico-radiological study of thirty-five cases
Br J Dermatol
(1985) - et al.
Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients
Quart J Med
(1983) - et al.
Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients
Respir Med
(2003)
Successful ultraviolet A1 treatment of cutaneous sarcoidosis
Br J Dermatol
Management of treatment-resistant cutaneous sarcoidosis with radiation
Am J Clin Oncol
Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters
BMC Dermatol
Cutaneous sarcoidosis successfully treated with topical tacrolimus
Br J Dermatol
Etanercept ameliorates sarcoidosis arthritis and skin disease
J Rheumatol
Treatment of cutaneous sarcoidosis with tranilast
J Dermatol
Cited by (125)
Cutaneous Sarcoidosis
2024, Clinics in Chest MedicineAnti-inflammatory Therapy for Sarcoidosis
2024, Clinics in Chest MedicineCutaneous Sarcoidosis
2023, Dermatologic ClinicsSarcoidosis
2021, Encyclopedia of Respiratory Medicine, Second EditionCorticosteroid refractory sarcoidosis
2020, Respiratory MedicineCitation Excerpt :This is particularly true for pulmonary sarcoidosis, where in one series, all 36 patients with an acute exacerbation of pulmonary sarcoidosis had a return of spirometry and symptoms to baseline after a median of 3 weeks of prednisone at a dose of 20 mg/day [3]. True corticosteroid failure is more common with the lupus pernio form of skin sarcoidosis [4], neurosarcoidosis [5,6], and cardiac sarcoidosis [7–10]. As is implied above, true corticosteroid failure appears to be somewhat organ dependent.
- 1
Drs. Stagaki, Mountford, and Lackland have no conflicts of interest to disclose.
- 2
Dr. Judson has received research grants from Celgene and Centocor.